Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 1 335.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (8.0%)
  • Dividend yield for the last twelve months 3.4%
  • Free cash flow yield -2.4% (LTM)
  • Share price is 21.2% higher than minimum and 30.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-70.0x vs
    )
  • For the last 3 months insiders bought company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+1.4%)92.515
year average price 113.89  


year start price 129.03 2024-02-27

max close price 132.96 2024-06-24

min close price 83.01 2025-02-14

current price 92.52 2025-02-25
Common stocks: 2 528 810 012

Dividend Yield:  3.4%
FCF Yield LTM: -2.4%
EV / LTM EBITDA: -70.0x
EV / EBITDA annualized: 8.7x
Last revenue growth (y/y):  +8.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +9.1%
Historical growth of EBITDA:  +6.9%
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 233 953
Net Debt ($m): 26 140
EV (Enterprise Value): 260 093
EBITDA LTM ($m): -3 715
EV / LTM EBITDA: -70.0x
Price to Book: 5.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-02-25prnewswire.com

MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

2025-02-25businesswire.com

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

2025-02-25prnewswire.com

Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

2025-02-24accessnewswire.com

Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24accessnewswire.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

2025-02-24accessnewswire.com

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24globenewswire.com

Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – MRK

2025-02-24accessnewswire.com

Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky

2025-02-24accessnewswire.com

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-02-24prnewswire.com

MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data